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Abstract: With regard to relapse and survival, early-stage high-grade serous ovarian (HGSOC) patients
comprise a heterogeneous group and there is no clear consensus on first-line treatment. Currently,
no prognostic markers are available for risk assessment by standard targeted immunohistochemistry
and novel approaches are urgently required. Here, we applied MALDI-imaging mass spectrometry
(MALDI-IMS), a new method to identify distinct mass profiles including protein signatures on
paraffin-embedded tissue sections. In search of prognostic biomarker candidates, we compared
proteomic profiles of primary tumor sections from early-stage HGSOC patients with either recurrent
(RD) or non-recurrent disease (N = 4; each group) as a proof of concept study. In total, MALDI-IMS
analysis resulted in 7537 spectra from the malignant tumor areas. Using receiver operating
characteristic (ROC) analysis, 151 peptides were able to discriminate between patients with RD
and non-RD (AUC > 0.6 or < 0.4; p < 0.01), and 13 of them could be annotated to proteins.
Strongest expression levels of specific peptides linked to Keratin type1 and Collagen alpha-2(I) were
observed and associated with poor prognosis (AUC > 0.7). These results confirm that in using IMS,
we could identify new candidates to predict clinical outcome and treatment extent for patients with
early-stage HGSOC.
Keywords: ovarian cancer; early-stage HGSOC; prognostic markers; MALDI-IMS
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1. Introduction
Epithelial ovarian cancer (EOC) is the leading cause of death within gynecological cancers in
the developed countries (http://seer.cancer.gov). Due to the lack of specific symptoms, EOC is often
detected at an advanced stage with a five-year survival rate less than 40% [1]. However, 25% of EOC
patients are diagnosed in early stage (I-II) as defined by Fédération Internationale de Gynécologie
et d’Obstétrique (FIGO), where the disease is often cured by surgery alone, or in combination with
platinum-based chemotherapy [2,3]. Even though the prognosis of patients with FIGO stage I-II
increases dramatically with treatment, with five-year survival rates between 80–90%, some subgroups
of early-stage EOC will relapse and 20–30% of these patients will finally succumb to the disease [4–6].
Older age, greater stage, higher grade and malignant cytology are independent prognostic factors for
recurrence [7]. Moreover, the prognosis differs between the histological subtypes with high-grade
serous ovarian cancer (HGSOC) being the most common one, accounting for 70–80% of ovarian
cancer-related deaths.
According to guidelines of the European Society for Medical Oncology (ESMO),
bilateral salpingo-oophorectomy, hysterectomy, omentectomy, peritoneal stripping and lymph
node sampling are recommended procedures for stage I and II HGSOC patients (https:
//www.esmo.org/guidelines/gynaecological-cancers/newly-diagnosed-and-relapsed-epithelial-
ovarian-carcinoma/esmo-esgo-consensus-conference-recommendations-on-ovarian-cancer) [8,9].
However, fertilization-sparing surgery (FSS) for women of childbearing age could be considered,
and be discussed individually [10]. Different criteria for selecting patients have been applied and
the debate over FSS in HGSOC is more than controversial as there are limited data on that issue.
Preoperative screening methods and comprehensive surgical staging for accurate disease classification
are mandatory [11,12]. In this context, one third of presumed stage I ovarian cancers were found to
be upstaged by the findings of dissemination in the peritoneal cavity [13]. Patients with high-risk
early-stage EOC, defined as stage I, grade 3, stage IC and II, as well as clear cell cancers, will require
adjuvant chemotherapy which has been shown to reduce the relapse rate by >60% in stage IC EOC
patients [14]. Hence, platinum-based chemotherapy is an important factor in treating these patients
with high-risk early-stage EOC with impact on both recurrence-free (RFS) and overall survival (OS).
Prognostic markers are needed to stratify patients into low- and high-risk groups in order to select
patients who will benefit from chemotherapy. The term EOC refers to at least four different histological
subtypes which is an important issue to take into account in the risk assessment of clinical progression.
The most aggressive histotype is HGSOC. Nevertheless, the optimal clinical management is still a
controversial debate and patients with early-stage high-grade serous EOC might be over-treated which
could potentially result in complications after radical surgical management and an increase in toxicity
of chemotherapy [15,16]. Hence, it is of utmost importance to identify novel diagnostic markers for
this patient cohort in order to improve the risk assessment of tumor recurrence. An optimal evaluation
of risk for progression would have the benefit of personalized chemotherapy, and reduced costs
and treatment side effects in patients with little risk for progression. Commonly used tissue-based
techniques, such as liquid chromatography-based mass spectrometry or gene expression profiling,
require large amounts of tissue material. Moreover, these methods do not enable a direct correlation
between differentially expressed molecular profiles and the tissue histology [17]. Matrix-assisted laser
desorption/ionization (MALDI) imaging mass spectrometry (IMS) has the advantage of combining
morphological features with protein expression in tissue. This technique enables spatially resolved
tissue assessment via specific molecular signatures (e.g., proteins, peptides, lipids and molecules of
cell metabolites) and allows their correlation with alterations in tissue histology [18–20] as well as
stages of ovarian cancer [21].
This recently developed diagnostic method of imaging mass spectrometry (MALDI-imaging
MS) has also been used for the rapid diagnosis and prognosis of patients [22–24], and to identify
peptide profiles spatially resolved directly on the paraffin-embedded tissue to depict and assign to the
histological and clinical pathological subtypes of cancer.
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Here, we have applied the method to detect a molecular signature of 13 peptides that predicts tumor
recurrence in patients with early-stage HGSOC. According to their specific sequence, these peptides
were allocated to a signature of proteins for risk stratification in support of clinical management of
patients with early-stage HGSOC.
2. Results
2.1. Accumulation of Proteomics Data by MALDI-IMS
The initial proteomic measurements were simultaneously carried out on primary tumor tissue
sections of early-stage HGSOC patients (n = 10) with either recurrent disease (RD) or non-recurrent
disease (non-RD), respectively. Mass spectra of primary tumor tissue sections of early-stage HGSOC
were extracted and statistical data analysis was performed by the SCiLS Lab software. In total,
506 aligned m/z values in a mass range between m/z 600 and 3.000 were extracted (Table S1). Average
spectra of primary tumor tissue sections of early-stage HGSOC are shown in Figure 1. The unsupervised
data analysis of the peptide signatures by probabilistic latent semantic analysis (pLSA) allowed the
discrimination of different patient groups via individual mass spectra compound intensity and spatial
distribution. Analysis of the peptide signatures by pLSA resulted in the discriminative compounds for
HGSOC patients with RD and non-RD. However, a third HGSOC patient group could be identified
which showed individual pLSA compounds which did not match to patients with RD nor patients
with non-RD (Figure S1).
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biologically independent spots (N = 10 each patient group). 
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Reassessment of the two patients in that subclass group by an experienced gynecological
pathologist showed that the previous immunohistological expression pattern in one of the patient
biopsies was not conclusive. As in high-grade serous ovarian carcinoma, p53 showed a mutated pattern,
but unlike typical high-grade serous carcinoma, CD56 and synaptophysin expressions were evenly
and strongly present. Moreover, the morphological picture indicates most likely an undifferentiated
non-small cell neuroendocrine carcinoma (NSCNEC) of the ovary. The second patient was re-classified
as pT2cG3 and hence not a HGSOC patient diagnosed at early stage. Therefore, samples of these two
outlier patients were not considered for further analysis.
Since considerable differences in stroma content occur within the sample cohort, malignant
compartments were evaluated in each core of early-stage HGSOC patients (N = 8). Mass spectra
of malignant areas from both annotated groups (N = 4, each group) were obtained and a statistical
comparison was performed using the SCiLS Lab software. In total, 612 m/z values from a mass range
between m/z 800 and 3.500 (threshold 31.42) were identified by peak-picking and used to compare
the tissue sections. Average exemplary spectra are shown for primary tumors of early-stage HGSOC
patients with RD and non-RD in Figure 1. In total, MALDI-IMS analysis resulted in 7537 spectra from
the entire patient cohort.
2.2. Discovery of Discriminative Peptide Signatures
In order to determine specific molecular signatures in HGSOC patients with RD and non-RD,
a pLSA based on the peptide signatures was performed and allowed the direct interpretation of score
images and loadings. Here, this unsupervised data analysis of the peptide signature enabled the
discrimination of both distinct patient groups (Figure 2).
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pairwise manner to obtain discriminative peptide values (m/z) using receiver operating characteristic 
(ROC) analysis. The ROC analysis resulted in 151 peptide values that were able to discriminate 
between patients with RD and non-RD (AUC > 0.6 or < 0.4; p < 0.01; Table S1). A selection is shown 
in Figure 3. 
For example, the peptide values 840.6 ± 0.2 Da, 1138.5 ± 0.2 Da and 1631.8 ± 0.2 Da denote high 
spatial intensity distribution in patients with recurrence of tumors, which can be visualized as a 
heatmap distribution across the tissue section (Figure 3). The peptide value 1631.8 ± 0.2 was 
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latent se antic analysis (pLSA). Score plots of the first three co ponents fro i aging ass
spectrometry (I S) spectra of primary tumors from patients without (−RD, in blue) and with recurrent
disease (+RD, in red) are shown.
2.3. Determination of Characteristic m/z Values of HGSOC Patients
The malignant compartments of the tumors were assigned and spectra were compared in a
pairwise manner to obtain discriminative peptide values (m/z) using receiver operating characteristic
(ROC) analysis. The ROC analysis resulted in 151 peptide values that were able to discriminate between
patients with RD and non-RD (AUC > 0.6 or < 0.4; p < 0.01; Table S1). A selection is shown in Figure 3.
For example, the peptide values 840.6 ± 0.2 Da, 1138.5 ± 0.2 Da and 1631.8 ± 0.2 Da denote
high spatial intensity distribution in patients with recurrence of tumors, which can be visualized as a
heatmap distribution across the tissue section (Figure 3). The peptide value 1631.8 ± 0.2 was associated
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with non-RD. The distribution of the most significantly expressed peptides within the groups is shown
in Figure 4.
2.4. Identification of Differentially Expressed Proteins
To improve the understanding of the disease progress and provide a method for personalized
pathology assessment of early-stage HGSOC, specific localized peptide values were investigated and
subsequently identified. Identification of these peptide markers provides important insights into the
disease mechanism as well as progression. Since a large number of isobaric ions and the presence of
so-called chimera spectra adversely affected the identification of m/z values by MS/MS (direct from
tissue section), we performed a corresponding “bottom-up” LC-MS/MS approach (Table S2) with
adjacent tissue sections, which enabled the identification of the obtained MALDI-IMS m/z values.
Out of the MADLI-IMS-derived discriminative m/z values between RD and non-RD HGSOC,
18 m/z values could be assigned to 13 proteins (Table 1).
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Table 1. Receiver operating characteristic (ROC) curve analysis reveals a prognostic protein signature
for early-stage HGSOC. Significantly differentially expressed proteins in primary tumors of patients
with recurrent compared with no-recurrent disease are listed (overexpressed, AUC values > 0.6,










Mr [Da] ∆ [Da] Ascension Protein
HGNC
Symbol
2705.026 2704.0181 0.7547 2704.1538 0.1358 K1C9_HUMAN Keratin, type I cytoskeletal 9 KRT9
1791.698 1790.6901 0.6250 1790.7204 0.0304 K1C9_HUMAN Keratin, type I cytoskeletal 9 KRT9
644.336 643.3281 0.7470 643.3653 0.0373 ACTB_HUMAN Actin, cytoplasmic 1 ACTB
840.564 839.5561 0.7407 839.4613 0.0947 CO1A2_HUMAN Collagen alpha-2(I) chain COL1A2
868.467 867.4591 0.7331 867.4563 0.0028 CO1A2_HUMAN Collagen alpha-2(I) chain COL1A2
2027.831 2026.8231 0.7008 2026.0093 0.8138 CO1A2_HUMAN Collagen alpha-2(I) chain COL1A2
1562.765 1561.7571 0.6930 1561.7849 0.0278 CO1A2_HUMAN Collagen alpha-2(I) chain COL1A2
1223.417 1222.4091 0.6262 1222.6054 0.1964 CO1A2_HUMAN Collagen alpha-2(I) chain COL1A2
700.444 699.4361 0.6388 699.4643 0.0282 RL37A_HUMAN 60S ribosomal protein L37a RPL37A
1790.797 1789.7891 0.6253 1789.8846 0.0956 ACTB_HUMAN Actin, cytoplasmic 1 ACTB
1743.691 1742.6831 0.6055 1742.8120 0.1290 H2B1N_HUMAN Histone H2B type 1-N HIST1H2BN
1550.764 1549.7561 0.6016 1549.8100 0.0540 ANXA1_HUMAN Annexin A1 ANXA1
858.566 857.5581 0.3975 857.4607 0.0974 CALD1_HUMAN Caldesmon CALD1
1157.708 1156.7001 0.3782 1156.6200 0.0800 APOA1_HUMAN Apolipoprotein A-I APOA1
1631.775 1630.7671 0.3682 1630.8236 0.0566 TBB5_HUMAN Tubulin beta chain TUBB
1751.792 1750.7841 0.3554 1750.0353 0.7488 H2B1K_HUMAN Histone H2B type 1-K HIST1H2BK
1055.394 1054.3861 0.3460 1054.5196 0.1335 4_HUMAN Histone H4 HIST1H4A




Figure 4. Examples of peptide distribution within groups of patients with (+RD) and without 
recurrent disease (−RD) by mass spectrometry intensity. (A) Density plot of skyline intensities over a 
continuous interval. Dashed lines indicate the distributions’ mean values. (B) Boxplot. 
More than one m/z value with similar discrimination characteristics was identified from Keratin 
type 1 and Collagen alpha-2(I) and was assigned to the observed m/z values from the MALDI-IMS 
experiment, hence correctly recognized (Table 1). 
2.5. Relatedness Between Patients with RD and Between Patients Without RD. 
The analysis was expanded and the peptide signature (discriminative m/z values) was applied 
to three additional early-stage patients with high-grade endometrioid ovarian cancer (HGEC), two 
of them with RD; one non-RD, and showed comparable peptide intensities in samples of HGSOC 
patients. A principal component analysis (PCA) was performed overlaying covariate influences onto 
the principal component space (Figure 5). 
Figure 4. Examples of peptide distribution within groups of patients with (+RD) and without recurrent
disease (−RD) by mass spectrometry intensity. (A) Density plot of skyline intensities over a continuous
interval. Dashed lines indicate the distributions’ mean values. (B) Boxplot.
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More than one m/z value with similar discrimination characteristics was identified from Keratin
type 1 and Collagen alpha-2(I) and was assigned to the observed m/z values from the MALDI-IMS
experiment, hence correctly recognized (Table 1).
2.5. Relatedness between Patients with RD and between Patients without RD
The analysis was expanded and the peptide signature (discriminative m/z values) was applied to
three additional early-stage patients with high-grade endometrioid ovarian cancer (HGEC), two of
them with RD; one non-RD, and showed comparable peptide intensities in samples of HGSOC
patients. A principal component analysis (PCA) was performed overlaying covariate influences onto




Figure 5. A biplot showing included samples of early-stage HGSOC patients as points. Additionally, 
three patients with high-grade endometrioid ovarian cancer (HGEC) were included in the analysis 
and marked with diamonds. Biplot axes indicate the influence of each peptide in the principal 
component space. The principal component analysis (PCA) shows a discrimination of patients with 
(+RD) and without recurrent disease (−RD). 
PCA confirmed the closer relatedness between patients with RD and between patients without 
RD. Inclusion of three early-stage HGEC patients showed similar relatedness. The variable markers 
cluster in two groups indicating correlated variables. The higher correlated group A comprises 1157.7 
± 0.2, 858.6 ± 0.2, 1751.8±0.2, 1753.0 ± 0.2 and 1055.4 ± 0.2 Da. The less correlated group B comprises 
the remaining peptides with 1631.8 ± 0.2 Da being negatively correlated (Figure 4A,B). The high 
proportion of variability explained by the two-dimensional principal subspace provides solid 
grounds for these correlations. 
3. Discussion 
In general, HGSOC patients diagnosed at early-stage have an excellent prognosis and concern 
arises that some of the early-stage HGSOCs are over-treated. Hence, there has been a debate about 
the optimal duration and chemotherapy treatment strategy, e.g., Carboplatin only, or combination 
regimens, four cycles vs. six cycles. However, a subgroup of patients will relapse and need therapies 
that are more intensive at time of diagnosis. It is therefore of great importance to identify these high-
risk patients in order to improve their clinical outcome. 
Currently, there are no reliable markers at hand for standard immunohistochemical assessment 
of this subpopulation. Here, we have used a novel approach using MALDI-IMS technology to screen 
for a prognostic peptide signature to support the clinical management of these patients. For this 
purpose, standardized protocols for MALDI-IMS sample preparation have been developed [25,26], 
which are intended to enable reliable exploration of molecular signatures as biomarkers and has been 
shown to provide valuable diagnostic and risk assessment capabilities for other diagnostically 
challenging neoplasms [27]. Our recently published data, showed that IMS can reliably detect the 
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3. Discussion
In general, HGSOC patients diagnosed at early-stage have an excellent prognosis and concern
arises that some of the early-stage HGSOCs are over-treated. Hence, there has been a debate about
the optimal duration and chemotherapy treatment strategy, e.g., Carboplatin only, or combination
regimens, four cycles vs. six cycles. However, a subgroup of patients will relapse and need therapies
that are more intensive at time of diagnosis. It is therefore of great importance to identify these high-risk
patients in order to improve their clinical outcome.
Currently, there are no reliable markers at hand for standard immunohistochemical assessment of
this subpopulation. Here, we have used a novel approach using MALDI-IMS technology to screen
for a prognostic peptide signature to support the clinical management of these patients. For this
purpose, standardized protocols for MALDI-IMS sample preparation have been developed [25,26],
which are intended to enable reliable exploration of molecular signatures as biomarkers and has
been shown to provide valuable diagnostic and risk assessment capabilities for other diagnostically
challenging neoplasms [27]. Our recently published data, showed that IMS can reliably detect the
histological subtypes of ovarian cancer [20]. In this presented study, proteomic analysis results 151
discriminative m/z values between early-stage HGSOC patients with either RD or non-RD. In order to
identify MALDI-IMS-derived m/z values, the “bottom-up”-nano liquid chromatography (nLC)-MS/MS
approach was performed on adjacent tissue sections. According to the IMS guidelines [28], the mass
difference between MALDI-IMS and LC-MS/MS m/z values should be less than 0.9 Da and requires the
identification of more than one peptide.
Specific peptides linked to Keratin type1, Actin, cytoplasmic 1 and Collagen alpha-2(I) were
observed to have the strongest expression levels in primary tumors from early-stage HGSOC patients
with RD and indicated greatest prognostic values (AUC > 0.7). A published reference database of
MALDI-IMS-derived peptide and protein values in various and in particular for ovarian cancer FFPE
tissue [29] was intended as support for the verification of protein identifications. The observed m/z
values 1562.8 ± 0.2 from Collagen alpha-2(I) and 1790.9 ± 0.2 Da from Actin, cytoplasmic 1 were also
determined and identified in MALDI-IMS studies of biopsies from lung tumor patients [30]. Through
regulation of various signaling pathways in cancer cells, Keratins, the epithelial-predominant members
of the intermediate filament superfamily, are involved in a number of processes in tumor progression [31].
KRT9 is one of the most common contaminants in proteomic mass spectrometry analyses, both in
ESI and MALDI mass spectrometry methods (see also reference [32]. These contaminations may
rarely have their source in the sample material (randomly distributed), but are more often introduced
during sample preparation (e.g., contamination from the environment like dust in solvents, buffers or
matrix) [32]. However, the difference with MALDI imaging experiments is that the m/z values can be
represented spatially in the tissue, such that contaminations would be evenly distributed over the whole
sample material. Therefore, the tissue microarrays (TMAs) are randomized and a control area outside
the tissue is measured as a control to exclude such contamination. No peptides (Isotopic pattern) and
salt adducts were detected in the control area. Only singles from alpha -Cyano-4-hydroxycinnamic
acid matrix clusters could be found with no influence on the data evaluation.
Moreover, both patient groups’ cores were included and randomly distributed on the same cover
slip. Therefore, it is unlikely to detect any significant differences. Furthermore, MALDI imaging
experiments predominantly address structural proteins, such as ECM molecules, since methodically an
enzymatic surface digestion of the tissue sections is performed. Excluding cytoskeleton proteins from
the analysis would be premature, especially since KRT9 is a cellular component of the cytoskeleton,
cytosol, extracellular region or membrane (see https://www.uniprot.org/uniprot/P35527---subcellular
location). Furthermore, a query of the kmplot.com (https://kmplot.com/analysis/) database showed a
significant decrease in overall survival (p < 0.0052) associated with high expression of KRT9 considering
only stage I EOC including HGSOC (p < 0.0028) patients (Figure S2). Therefore, our KRT9 MALDI-IMS
measurement is unlikely a result of contamination.
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The major sources of collagen expression are stromal cells with increased collagen production and
disposition in the stromal compartment has been shown to be associated with breast cancer development
and progression [33,34]. Nevertheless, it was also demonstrated that expression of collagen by ovarian
cancer cells, including Collagen alpha-2(I), could increase drug resistance by inhibiting the penetration
of the drug into the cancer tissue as well as increase resistance to apoptosis [35].
The analysis of three additional early-stage HGEC patients (two with RD; one without RD)
showed comparable measured peptide intensities to the HGSOC patients. A multivariate regression
was not feasible due to an insufficient number of observations [36]. However, reduction in covariates
(dimension reduction), such as in a PCA, showed the discriminative capacity of the proposed prognostic
marker candidates for patients with early-stage of either HGEC or HGSOC (Figure 5). Peptide markers
separated into two distinct groups based on the correlation between them.
Even though the utilized sample size of four patients for each group is not sufficient for clinical
validation, the purpose of this proof of concept study is to identify prognostic marker candidates.
Consequently, validation of applicability of the proposed prognostic marker candidates, including for
endometrioid carcinomas, necessitates subsequent high-sample size follow-up studies.
Moreover, changes in the tumor microenvironment in response to malignant transformation
have been neglected in the past and need to be considered as a suitable compartment for biomarker
discovery. So far, a major limitation of dissecting the stromal signature has been a lack of suitable
methods. IMS is able to provide spatial information of protein signatures in both compartments.
Unfortunately, the quality of the adjacent stroma in the majority of cores from the tumor tissue was not
suitable for further assessment but should be included and subject of future prognostic biomarker
research for early-stage HGSOC patients.
Eventually, a profound understanding of the biology in early-stage HGSOC might result in a
redefinition of high-risk early-stage EOC to develop novel therapeutic approaches. However, this will
need molecular characterization supported by RNA-Seq and high-resolution proteomics data from
micro-dissected malignant and adjacent stroma compartments. Nevertheless, the identification of the
subpopulation of patients developing recurrent tumors is an unmet clinical need. Here, we show that
MALDI-IMS technology has the potential to make a meaningful impact for risk assessment and, hence,
patient outcome.
4. Materials and Methods
4.1. Clinicopathological Parameters of Patient Cohort
All samples were collected at Charité, Department for Gynecology at surgery after patients gave
their informed consent. Sample collection was permitted by the local ethics committee of the Charité
Medical University Berlin (AVD-No. 2004-000034) and conducted according to the Declaration of
Helsinki. All patients were of white caucasian background and received an accurate staging via
laparotomy, including lymph node sampling. Diagnosis of the early-stage of the high-grade serous
subtype of EOC was confirmed by an experienced gynecological pathologist. Adjuvant chemotherapy
regime was applied to all patients based on carboplatin in combination with paclitaxel. Detailed
descriptions of clinicopathological parameters of patients are shown in Table 2.
4.2. Procedure of MALDI-Imaging
Tissue microarrays (TMAs) of formalin-fixed paraffin-embedded tissue of patients diagnosed
at early-stage HGSOC were designed and prepared at the Institute of Pathology, Charité Medical
University Berlin. For MALDI-imaging, a 6 µm section was prepared from a paraffin block on
a microtome and transferred onto Indium-Tin-Oxide slides (Bruker Daltonik, Bremen, Germany)
through decreasing concentrations of ethanol (modified by Caprioli et al.) [37] and antigen
retrieval was performed (modified by Gustafsson et al.) [38]. Trypsin and matrix solutions
(α-Cyano-4-hydroxycinnamic acid) were deposited by an automated spraying device (HTX Sprayer).
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An amount of 550 µL trypsin solution (20µg, 20mM ammonium bicarbonate) was applied onto
the section. After tissue incubation (2 h at 50 ◦C; moist chamber), matrix solution (1 mL 7g/L
α-cyano-4-hydroxycinnamic acid in 50% acetonitrile and 1% trifluoroacetic acid) was applied using a
HTX Sprayer (75 ◦C, estimate cycle 1.80).
Table 2. Clinicopathological characteristics of patients. All patients received adjuvant chemotherapy
for numbers of cycles as indicated in the table. Follow-ups of patients were performed for at least
5 years, if no relapse occurred, or till development of recurrent disease (RD).
Patients (−RD)
Age 68 60 68 67
FIGO stage IA IC IA IC
Grade G3 G2 G3 G3
Presence of ascites <500 mL <500 mL <500 mL no
Number of cycles 6 6 4 6
Recurrence (months) NA NA NA NA
Patients (+RD)
Age 44 52 67 57
FIGO stage IIB IIA IA IIA
Grade G3 G3 G3 G3
Presence of ascites >500 mL no No no
Number of cycles 6 9 6 6
Recurrence (months) 13 12 54 16
4.3. MALDI Imaging Analysis
Analyses were performed on 10 biologically independent cores of biopsies for each patient group.
MALDI-IMS data acquisition was executed in reflector mode, detection range of m/z 800–3200, 500 laser
shots per spot, sampling rate of 1.25 GS/s and raster width of 50 µm on Rapiflex MALDI-TOF/ using
flexControl 3.0 and flexImaging 3.0 (Bruker Daltonik). External calibration was performed using
a peptide calibration standard (Bruker Daltonik) and spectra processed in flexAnalysis 3.0 (Bruker
Daltonik). In order to exclude potential contamination like sodium adducts or peptides, control areas
outside the tissue were also analyzed. After MALDI-imaging experiments, the matrix was removed
with 70% ethanol and the tissue sections were stained with hematoxylin and eosin (H&E) as histological
overview staining [37].
4.4. Data Processing
Statistical data analysis was performed using the SCiLS Lab software (Version2015b, SCiLS GmbH,
Bremen, Germany). MALDI-IMS raw data were imported into the SCiLS Lab software and converted to
the SCiLS Lab file format. Simultaneous preprocessing of all data sets was carried out to ensure better
comparability between the sample sets. Imported data were pre-processed by convolution baseline
removal (width: 20) and total ion count (TIC) normalization. Segmentation pipelines as published
previously were performed for peak-finding and alignment [19,39,40]. Peaks were selected using the
orthogonal matching pursuit (OMP) algorithm [41] and top down segmentations were performed
by bisecting k-means clustering, ±0.156 Da interval width, mean interval processing and medium
smoothing strength [39–41]. For convolutional neural networks evaluation, raw data from region spots
and m/z values were exported from SCiLS Lab SW as csv format. Two approaches based on different
principles were performed: first, an unsupervised approach, probabilistic latent semantic analysis
(pLSA), to discriminate both groups, and another supervised approach, receiver operating characteristic
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(ROC) analysis, to detect characteristic peptide values. To define common molecular features among
the sample sets, unsupervised multivariate classification methods for mass spectra were applied:
probabilistic latent semantic analysis (pLSA) was performed as previously described [42,43]. pLSA was
performed with five components and the following settings: (i) interval width of ± 0.156 Da, and (ii)
individual spectra and deterministic initialization. Receiver operating characteristic analysis (ROC)
was used to assess the quality of all m/z values within specific ROIs to discriminate between recurrent
and non-recurrent HGSOC tumor tissue. For this method, the number of spectra in the ROIs of both
groups should be approximately the same. If that was not the case, 1500 randomly selected spectra per
ROI/group were used. To determine statistical significance, discriminating m/z values (peaks) with
an AUC < 0.35 or > 0.65 were subsequently analyzed using the Wilcoxon rank sum test. m/z values
with delta peak intensities of >0.7 and <0.3 (p < 0.001) were assumed as potential markers. Figures
were created using the SCiLS Lab software (Bruker, Bremen, Germany) and R packages “ggplot2”
and “ggbiplot”.”
4.5. Identification of Peptides by “Bottom-Up”-Nhplc Mass Spectrometry
To identify m/z values, complementary protein identification was performed on adjacent
tissue sections by a “bottom-up”-nano liquid chromatography (nLC)-MS/MS approach as published
previously [19]. Briefly, tissue digestion (20 µg trypsin, 20 mM ammonium bicarbonate/acetonitrile 9:1)
was performed via ImagePrep (Bruker Daltonik). Peptides for nUPLC-MS/MS analysis were extracted
directly from adjacent tissue sections into 40 µL of 0.1% triflouroaceticacid (TFA; 15 min incubation at
room temperature). Peptides were separated (60% acetonitrile/ in 0.1% formic acid) using an analytical
UPLC System (Thermo Dionex Ultimate 3000, Acclaim PepMap RSLC C18 column 75µmx 15 cm;
flow rate 200 nL/min, 70 min) and analyzed via Impact II (QTOF-MS, Bruker Daltonik). All raw spectra
from the MS/MS measurement were converted to mascot generic files (.mgf) using the ProteinScape
software [44]. Mass spectra were analyzed using the Mascot search engine (version 2.4, MatrixScience;
UK) searching the UniPort database. The search was performed with the following set of parameters:
(i) taxonomy: human; (ii) proteolytic enzyme: trypsin; (iii) peptide tolerance: 10ppm; (iv) maximum of
accepted missed cleavages: 1; (v) peptide charge: 2+, 3+, 4+; (vi) variable modification: oxidation
(M); (vii) MS/MS tolerance: 0.8Da; and (viii) MOWSE score > 25. Identification of MALDI-IMS m/z
values by using an LC-MS/MS reference list requires the accordance of more than one peptide (mass
differences <0.9 Da) to subsequently correctly assign the corresponding protein [45]. Peptides with
lowest mass difference to the LC-MS/MS reference list value were assumed as a match.
5. Conclusions
Epithelial ovarian cancer (EOC) has the highest mortality rate of the gynecological malignancies
worldwide, with HGSOC representing the most common and aggressive histological subtype.
Even though HGSOC patients diagnosed at early-stage have an excellent prognosis, a subgroup
of patients will relapse and need therapies that are more intensive at time of diagnosis. It is therefore of
great importance to identify these high-risk patients in order to improve their clinical outcome. In this
proof of concept study, we have applied a novel approach using MALDI-IMS technology to identify a
candidate prognostic peptide signature to support the clinical management of these patients. However,
there is still a need for a robust validation of our candidate signature based on a higher-size patient
cohort that should be addressed in the future. This includes implementing the identified and validated
prognostic peptide signature as part of prospective studies in the clinical routine.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/8/2000/s1,
Figure S1: Discrimination of molecular signatures for groups of HGSOC patients via probabilistic latent semantic
analysis (pLSA), Figure S2: Kaplan–Meier curves displaying the estimated overall survival probability of EOC
patients with regard KRT9 expression, Table S1: m/z values from IMS and the corresponding identification and
AUC values, Table S2: LC-MS reference list of ovarian cancer tissue.
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